Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis
Metadatos
Mostrar el registro completo del ítemAutor
Muñoz-Bravo, Carlos; Lozano Lorca, Macarena; Kouiti, Malak; González-Palacios Torres, Carla; Barrios Rodríguez, Rocío; Jiménez Moleón, José JuanEditorial
Frontiers
Materia
Serum copper Cardiovascular disease Cardiovascular mortality Stroke Myocardial infarction Meta-analysis Cardiovascular events
Fecha
2023-06-27Referencia bibliográfica
Muñoz-Bravo C, Soler-Iborte E, Lozano- Lorca M, Kouiti M, González-Palacios Torres C, Barrios-Rodríguez R and Jiménez-Moleón JJ (2023) Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis. Front. Cardiovasc. Med. 10:1217748. [doi: 10.3389/fcvm.2023.1217748]
Resumen
Background: Despite the fact that several studies have investigated the association
between serum copper levels (S-Cu) and the risk of cardiovascular diseases, this
relationship remains unclear. The aims of this study were to investigate the
association between S-Cu and risk of major adverse cardiovascular events
(MACE), including total stroke, ischemic stroke, hemorrhagic stroke, myocardial
infarction and cardiovascular mortality, and identify potential sources of results
heterogeneity.
Methods: We carried out a systematic review and meta-analysis. The selection
criteria were: (1) Observational studies (cohort studies, case-control studies and
hybrid studies); (2) Studies containing quantitative data about the relationship
between S-Cu and risk of MACE; (3) Estimating association measures; and
(4) Studies written in English, French or Spanish. Overall pooled Odds ratio
(pOR) and 95% confidence intervals (95% CI) of MACE for the highest vs. lowest
S-Cu category were calculated using random-effects models.
Results: Sixteen studies with a total of 41,322 participants were included in the
meta-analysis: 10 prospective cohort studies, 5 nested case-control studies and 1
case-control study. Comparing highest vs. lowest category, high S-Cu levels were
associated with total stroke (pOR: 1.49, 95% CI 1.22–1.82; I2=0%, p=0.54),
myocardial infarction (pOR: 1.31, 95% CI 1.17–1.46; I2=0.0%, p=0.92) and
cardiovascular mortality (pOR: 1.60, 95% CI 1.39–1.86; I2=0.0%, p=0.54).
Subgroup analysis showed that studies with a hybrid design had higher risks for
cardiovascular mortality (pOR: 3.42, 95% CI 1.98–5.92) and ischemic stroke (pOR:
1.54, 95% CI 1.30–1.83).
Conclusion: High S-Cu levels were associated with an increased risk of total stroke,
myocardial infarction and cardiovascular mortality. Hybrid studies seems to modify
the strength of the association between S-Cu and the risk of cardiovascular
mortality and ischemic stroke